02910: Open-Label, Phase-2 Clinical Trial of Chlorambucil and Toceranib for Canine Mast Cell Tumors

Grant Status: Closed

Grant Amount: $72,156
Kristen Weishaar, DVM, MS; Colorado State University
March 1, 2021 - February 29, 2024

Sponsor(s): Golden Retriever FoundationĀ®, Labrador Retriever Club, Inc., Vizsla Club of America Welfare Foundation

Breed(s): Chinese Shar-Pei, Boxer, Labrador Retriever, Boston Terrier, Rhodesian Ridgeback, Vizsla, Standard Schnauzer, Beagle, Bulldog, Weimaraner, -All Dogs
Research Program Area: Oncology
Donate to Support this Research Program Area


Mast cell tumor (MCT) is the most common malignant canine skin tumor. Although all breeds are at risk, Boxers, Boston Terriers, Bulldogs, Labrador Retrievers, Beagles, Viszlas, Rhodesian Ridgebacks, Weimaraners, Shar-Peis and Schnauzers are predisposed. While surgery remains the main treatment for most MCT, a subset have a high potential for eventual recurrence and metastasis and require systemic medical therapy following surgery in an attempt to delay or prevent eventual metastasis. Furthermore, many dogs may present with disease that is not amenable to resection owing to size, location, or multifocal or disseminated disease. Medical therapy for these patients remains suboptimal. Both low dose continuous (metronomic) chlorambucil (MC) and toceranib (TOC, Palladia) have some reported activity against MCT, and the combination is sometimes utilized clinically. However, (1) there have been, to date, no studies demonstrating that the empirically determined dose of MC exerts biologic effects; (2) the combination of MC and TOC has not been systematically evaluated for safety or efficacy in any tumor type. Investigators will address these critical knowledge gaps with a clinical trial to characterize the antitumor effects and adverse effect profile associated with chlorambucil/TOC in dogs with measurable MCT and quantify changes in circulating Treg and MDSC following MC and subsequent TOC treatment in the patient population. Lastly, they aim to describe alterations in previously identified biomarkers of TOC exposure and interrogate novel MC/TOC exposure biomarkers through gene-expression profiling of peripheral blood mononuclear cells. They hypothesize that a combination of MC and TOC will be well tolerated and will cooperatively reduce circulating regulatory T cells (Treg) +/- myeloid-derived suppressor cells (MDSC) in dogs with MCT, with the potential to translate into improved tumor control.

This study is looking for participants. Learn more here!


Not at this time.

Help Future Generations of Dogs

Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.

Learn How to Help

Get Canine Health News:
Please leave this field empty
American Kennel Club Canine Health Foundation, Inc

8051 Arco Corporate Dr.
Suite 300
Raleigh, NC 27617

Tax ID# 13-3813813


Ā© 2021 AKC Canine Health Foundation | Privacy Policy | Site Map

Site by Blackbaud, Inc.